Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Advanced Solid Tumors

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • University of California San Diego, San Diego, California, United States

  • Sarcoma Oncology Center, Santa Monica, California, United States

  • Moffitt Cancer Center, Tampa, Florida, United States

  • University of Chicago, Chicago, Illinois, United States

  • Massachusetts General Hospital, Boston, Massachusetts, United States

  • Dana-Farber Cancer Institute, Boston, Massachusetts, United States

  • University of Pennsylvania, Philadelphia, Pennsylvania, United States

  • University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

  • University of Texas - M.D. Anderson Cancer Center, Houston, Texas, United States

  • NEXT Oncology Houston, Houston, Texas, United States

  • NEXT Virginia, Fairfax, Virginia, United States

  • Hopital Saint - Andre - CHU de Bordeaux, Bordeaux, France

  • Centre Léon Bérard, Lyon, France

  • Hôpital de la Timone, Marseille, France

  • Hospital Universitario Vall d'Hebron, Barcelona, Spain

  • Hospital Universitario Ramón y Cajal, Madrid, Spain

  • START Madrid - Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain

  • Hospital Universitario 12 de Octubre, Madrid, Spain

  • Hospital Clínico Universitario de Valencia, Valencia, Spain